Related Experiment Video
Updated: Aug 30, 2026

Recombinant Collagen I Peptide Microcarriers for Cell Expansion and Their Potential Use As Cell Delivery System in a Bioreactor Model
Published on: February 7, 2018
Global regulatory registration requirements for collagen-based combination products: points to consider
Judith E O'Grady1, Diana M Bordon
1Regulatory Affairs, Integra LifeSciences Corporation, 311 Enterprise Drive, Plainsboro, NJ 08536, USA. jogrady@integra-ls.com
Abstract:
Collagen-based medical products provide an ideal and unique matrix for the delivery of drugs, biologics and other therapeutic agents. Collagen has a long history of safety and effectiveness. Collagen is biodegradable with minimal tissue reaction. Regulatory requirements for approval of collagen-based combination products are changing as more high technology combinations are developed. There are special considerations that need to be addressed for collagen products. Products of animal origin must meet specific requirements in regards to safety factors regarding Transmissable Spongiform Encephalopathies. Global regulatory registration requirements and special controls are presented.
